AI platform nabs $2m to connect patients and providers with clinical trials

By Melissa Fassbender contact

- Last updated on GMT

Mendel.ai automates matching cancer patients to clinical trials. (Image: iStock/ktsimage)
Mendel.ai automates matching cancer patients to clinical trials. (Image: iStock/ktsimage)

Related tags: Clinical trials, Medicine, Physician

Mendel.ai has raised $2m in seed funding to advance its artificial intelligence engine that connects doctors and patients with clinical trials.

Karim Galil, MD, founder and CEO of Mendel Health, Inc told us he was tired of losing patients to cancer only to later find out about a treatment she hadn’t considered. “Every year 700k papers are published in medicine and an average physician can read 200​,” he explained.

For this reason, Galil worked to develop Mendel.ai, which he said democratizes breakthroughs in medicine.

Contrary to our limited human brains, Mendel's technology can sift through the collective knowledge of medicine and make connections based on a patient's medical records​,” he said.

Mendel combines neuro-linguistic programming (NLP) with deep learning models, trained by the company’s in-house team of oncologists and physicians, to essentially enable the program “to read and think like an oncologist,​” Galil explained.

The program identifies key attributes and events in a patient's medical record, sifts for papers or clinical trials that target similar patient profiles, and makes a recommendation to the physician, he added.

With funding in tow, Galil said he is planning to expand the company’s team of AI scientists, hire more physicians and oncologists, and integrate the technology with three health institutes/organizations.

The next steps involve testing the algorithms in real clinical settings and expanding the matching services outside clinical trials to include approved treatments.

We are building Jarvis for physicians. An AI assistant that can make any physician a super hero,​” said Galil. “This can be the fine line between life and death for many patients​.”

Investing in AI

When the team at DCM Ventures, the company that co-led the investment, met Galil, Kyle Lui said the venture capital firm saw “a big opportunity to get behind a passionate team where applied AI could save lives​.”

According to Lui, a principal at DCM, healthcare is a $3tn market ripe for AI disruption.

Cancer centers and oncologists spend a disproportionate amount of time matching patients to potential trials — reading through countless PDFs where relevant data on both sides — patient data and trial requirements are often in unstructured data​,” he added.

Even if a doctor reads all of the clinical trials he/she can in a day, it doesn’t come close to the number of trials that exist – which is missed opportunity​.”

Lui said what used to take a cancer team tens of hours can be done by Mendel in one-tenth the time, “and more thoroughly​.”

The next step will be finding a way to use patient data from EMR’s to provide better overall care by preventing missed opportunities in terms of treatment, diagnosis, and preventative healthcare, Lui explained.

For Mendel, we are making introductions to other health systems, other relevant startups for potential partners, and of course, helping to build the team​,” he added.

Mendel has landed its first integration with the UCLA-affiliated Comprehensive Blood and Cancer Center and Lui said the firm expects the company will continue to meet its business milestones and attract additional funding rounds.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars